Company Overview and News

 
DBV Technologies : Information mensuelle relative au nombre total des droits de vote et d'actions composant le capital social

2018-10-09 globenewswire
Monthly information regarding the total number of voting rights and total number of shares of the Company
DBV

 
DBV Technologies: Monthly information regarding the total number of voting rights and total number of shares of the Company

2018-10-09 globenewswire
Monthly information regarding the total number of voting rights and total number of shares of the Company
DBV

3
Aimmune and DBV Eye the Finish Line for Peanut Allergy Treatments

2018-09-28 biospace
An estimated 15 million people in the United States have allergies to more than 170 different foods, according to the non-profit Food Allergy Research and Education. New health data suggests the frequency of food allergies in children under 18 has risen 70 percent since 1997, CNBC reported.
DBV FINL

 
DBV Technologies invitée à présenter à la Cantor Global Healthcare Conference

2018-09-25 globenewswire
DBV Technologies (Euronext : DBV - ISIN : FR0010417345 - Nasdaq : DBVT), société biopharmaceutique française, annonce aujourd'hui que Susanna Mesa, Chief Business Officer, présentera lors de la Cantor Global Healthcare Conference qui aura lieu à New York, NY le Mardi 2 octobre 2018 à 9h10 heure locale (15h10 heure française).
DBV

 
DBV Technologies to Present at the Cantor Global Healthcare Conference

2018-09-25 globenewswire
DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Susanna Mesa, Chief Business Officer, will present at the Cantor Global Healthcare Conference on Tuesday, October 2, 2018, at 9:10am EST in New York, NY.
DBV

 
DBV Technologies Announces Positive DSMB Review of Part A of Phase III Study in Peanut-Allergic Toddlers

2018-09-12 globenewswire
DBV Technologies Announces Positive DSMB Review of Part A of Phase III Study in Peanut-Allergic Toddlers
DBV

 
DBV Technologies annonce la revue positive par le DSMB des résultats du premier volet de sa phase III réalisé sur de jeunes enfants allergiques à l'arachide

2018-09-12 globenewswire
DBV Technologies annonce la revue positive par le DSMB des résultats du premier volet de sa phase III réalisé sur de jeunes enfants allergiques à l'arachide
DBV

 
DBV Technologies: Monthly information regarding the total number of voting rights and total number of shares of the Company

2018-09-07 globenewswire
Monthly information regarding the total number of voting rights and total number of shares of the Company
DBV

 
DBV Technologies : Information mensuelle relative au nombre total des droits de vote et d'actions composant le capital social

2018-09-07 globenewswire
Information mensuelle relative au nombre total des droits de vote et d'actions composant le capital social
DBV

 
DBV Technologies : Résultats financiers du premier semestre 2018

2018-09-07 globenewswire
DBV Technologies (Euronext: DBV - ISIN : FR0010417345 - NASDAQ : DBVT), société biopharmaceutique française, a annoncé aujourd'hui ses résultats financiers du premier semestre 2018. Le Rapport Financier Semestriel (information réglementée) est disponible sur le site de la Société, www.dbv-technologies.com. Les états financiers du premier semestre 2018 ont fait l'objet d'un examen limité par les Commissaires aux Comptes de la Société.
DBV

 
DBV Technologies : Reports First Half 2018 Financial Results

2018-09-07 globenewswire
DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today reported first half 2018 financial results. The interim financial report is available on the Investor Relations section of the Company's website, https://www.dbv-technologies.com/investor-relations/. First half 2018 financial statements were subject to a limited review by the Company's external auditors.
DBV

 
DBV Technologies, Geneva University Hospitals and BioNet-Asia Presented Additional Phase I Data on the Use of an Investigational Epicutaneous Patch in Boosting Pertussis Vaccination at the ECI

2018-09-05 globenewswire
DBV Technologies, Geneva University Hospitals and BioNet-Asia Presented Additional Phase I Data on the Use of an Investigational Epicutaneous Patch in Boosting Pertussis Vaccination at the European Congress of Immunology
DBV

 
DBV, les HUG et BioNet ont présenté les données additionnelles d'une étude de phase I sur l'utilisation d'un patch épicutané expérimental en vaccination de rappel contre la coqueluche lors de l'ECI

2018-09-05 globenewswire
DBV Technologies, les Hôpitaux Universitaires de Genève et BioNet-Asia ont présenté les données additionnelles d'une étude de phase I sur l'utilisation d'un patch épicutané expérimental en vaccination de rappel contre la coqueluche lors de l'European Congress of Immunology
DBV

 
DBV Technologies invitée à présenter lors des prochaines Conférences Investisseurs

2018-08-31 globenewswire
DBV Technologies (Euronext : DBV - ISIN : FR0010417345 - Nasdaq : DBVT), société biopharmaceutique française, annonce aujourd'hui que des membres de son management ont été invités à présenter ainsi qu'à tenir des rendez-vous investisseurs en septembre 2018 lors des conférences investisseurs suivantes :
DBV MS

 
DBV Technologies to Attend Upcoming Investor Conferences

2018-08-31 globenewswire
DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that members of its management team will present and host investor meetings at the following investor conferences in September 2018:
DBV MS

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...